$VRSK

AllianceBernstein (VRSK) files 13G/A showing 6.0M Verisk Analytics shares held

AllianceBernstein L.P. filed an amended Schedule 13G/A reporting beneficial ownership of 6,008,136 shares of Verisk Analytics Inc common stock, about 4.6% of the outstanding class, held for investment purposes in client discretionary accounts. The filing cites sole voting power over 5,773,111 shares and sole dispositive power over 6,001,448 shares.

Original reporting
Published Aug 14, 2026, 7:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 16, 2026, 1:43 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$VRSK
Neutral
medium confidence
Mentioned
$VRSK
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$VRSKNeutralLow
01

Why it matters

Traders may monitor ownership changes for potential future activism or control shifts, but this specific disclosure reads as passive and does not describe any corporate action by Verisk.

02

Market read

A new SEC ownership filing updates the reported beneficial stake, but the article provides no catalyst beyond transparency.

03

What to watch

The article does not state whether the stake increased or decreased versus the prior filing, nor does it provide transaction dates or cost basis, limiting inference about momentum or urgency.

Relevance 4/10Novelty 4/10Timing: filed Aug 14, 2026 (new SEC 13G/A disclosure)

Background

The article summarizes an amended Schedule 13G/A in which AllianceBernstein L.P. reports beneficial ownership of Verisk Analytics common stock for investment purposes.

Company-level read

Ticker impact

$VRSKNeutralMedium confidence
Context

AllianceBernstein filed an amended Schedule 13G/A reporting 6,008,136 Verisk Analytics shares, 4.6% of the class, for investment purposes.

Expected impact

Low likelihood of a sustained move; any reaction would be modest and short-lived.

Evidence & confidence

The filing describes beneficial ownership and voting/dispositive powers but does not indicate a takeover, tender, or new business development. Schedule 13G/A amendments can matter for positioning, yet the article provides no intent to change strategy or control.

Market effects

Minimal. A large institutional holder’s passive stake update does not change sector fundamentals.

None indicated.

None indicated.

Counterpoint

Even without control intent, a rising or newly disclosed stake can signal longer-term conviction and influence other investors’ positioning.

Key entities

  • Verisk Analytics Inc

    Subject of the Schedule 13G/A amendment, with AllianceBernstein reporting 6,008,136 shares beneficially owned (4.6%).

  • AllianceBernstein L.P.

    Majority-owned subsidiary of Equitable Holdings that filed the amended Schedule 13G/A reporting the stake.

  • Equitable Holdings, Inc.

    Parent of AllianceBernstein; the filing states independent management and separate reporting.

Related articles

$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer

$VRSKMed

Verisk Told It Can't Abandon $2.35B AccuLynx Deal

Delaware Chancery Court ruled that Verisk Analytics Inc. improperly exited its $2.35 billion acquisition of AccuLynx, according to the court. The decision requires Verisk to proceed with the deal, affecting the timing and terms of the insurance data and software transaction for investors.

$VRSKMed

Why is Verisk Analytics stock sliding today?

Verisk Analytics shares fell 5.6% after the Delaware Chancery Court ruled Verisk must proceed with its $2.35 billion AccuLynx acquisition. The court said Verisk’s conduct invalidated its Dec 2025 deal termination and awarded AccuLynx damages plus interest. Verisk said it strongly disagrees and is evaluating next steps, including a possible appeal, while FTC antitrust review remains unresolved.

$VRSKMedAI 8/10

Verisk stock falls after court rejects $2.35B merger termination

Verisk Analytics (NASDAQ:VRSK) shares fell about 5.5% after a Delaware Chancery Court rejected Verisk’s bid to terminate its $2.35B acquisition of AccuLynx. The court said Verisk’s termination was invalid and AccuLynx is owed damages for direct costs plus interest. Verisk said it strongly disagrees and is evaluating options, including an appeal.

$VRSKMedAI 8/10

Verisk Slides as Court Revives AccuLynx Deal Fight

Verisk Analytics (VRSK) fell about 5% as a Delaware Court of Chancery ruling revived its dispute over the terminated AccuLynx acquisition. Verisk agreed to buy AccuLynx in July 2025 and terminated in Dec. 2025. The court required Verisk to pursue regulatory approval efforts for the $2.35 billion deal. Verisk reported Q2 2026 revenue of $806 million.